By Iain Gilbert
Date: Tuesday 26 Aug 2025
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
Total Voting Rights | 01-Sep-2025 | 07:00 | RNS |
PDMR Dealings | 22-Aug-2025 | 15:36 | RNS |
Holding(s) in Company | 21-Aug-2025 | 10:24 | RNS |
Admission of Shares and Total Voting Rights | 20-Aug-2025 | 07:00 | RNS |
PDMR Dealings | 15-Aug-2025 | 13:45 | RNS |
Need to know: Opec cuts forecast ... Tesco cuts ... | 16-Aug-2008 | Times |
Need to know | 10-May-2008 | Times |
DSG International may be losing its spark | 12-Feb-2008 | Telegraph |
Oxford BioMedica clinches $690m licensing deal f... | 29-Mar-2007 | The Independent |
Oxford Biomedica seals €518m deal with Sanofi ov... | 29-Mar-2007 | Times |
No recent information was found.
Currency | UK Pounds |
Share Price | 578.00p |
Change Today | -22.00p |
% Change | -3.67 % |
52 Week High | 605.00p |
52 Week Low | 232.50p |
Volume | 344,451 |
Shares Issued | 120.18m |
Market Cap | £694.65m |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 4 |
Buy | 2 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 10 |
No dividends found |
Time | Volume / Share Price |
16:36 | 83,000 @ 598.23p |
16:39 | 939 @ 578.00p |
16:39 | 1,200 @ 578.00p |
16:39 | 613 @ 578.00p |
16:39 | 656 @ 578.00p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research